KR20190026317A - Composition for Pain Relief Comprising Natural Combined Oil - Google Patents
Composition for Pain Relief Comprising Natural Combined Oil Download PDFInfo
- Publication number
- KR20190026317A KR20190026317A KR1020170113032A KR20170113032A KR20190026317A KR 20190026317 A KR20190026317 A KR 20190026317A KR 1020170113032 A KR1020170113032 A KR 1020170113032A KR 20170113032 A KR20170113032 A KR 20170113032A KR 20190026317 A KR20190026317 A KR 20190026317A
- Authority
- KR
- South Korea
- Prior art keywords
- oil
- pain
- natural
- weight
- composition
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 62
- 230000036407 pain Effects 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 239000003921 oil Substances 0.000 claims description 74
- 235000019198 oils Nutrition 0.000 claims description 74
- 238000000034 method Methods 0.000 claims description 24
- 229930014626 natural product Natural products 0.000 claims description 17
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000341 volatile oil Substances 0.000 claims description 7
- 244000246386 Mentha pulegium Species 0.000 claims description 6
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 6
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 6
- 235000001050 hortel pimenta Nutrition 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 5
- 235000019477 peppermint oil Nutrition 0.000 claims description 5
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 5
- 210000001364 upper extremity Anatomy 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000001569 carbon dioxide Substances 0.000 claims description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000002981 blocking agent Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 229940100616 topical oil Drugs 0.000 claims description 3
- 239000004902 Softening Agent Substances 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 239000003349 gelling agent Substances 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000002304 perfume Substances 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 244000024251 Aralia cordata Species 0.000 claims 1
- 235000014722 Aralia cordata Nutrition 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 239000004088 foaming agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 230000008719 thickening Effects 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 230000008859 change Effects 0.000 abstract description 8
- 230000000007 visual effect Effects 0.000 abstract description 4
- 235000006679 Mentha X verticillata Nutrition 0.000 abstract description 3
- 235000002899 Mentha suaveolens Nutrition 0.000 abstract description 3
- 235000001636 Mentha x rotundifolia Nutrition 0.000 abstract description 3
- 240000000249 Morus alba Species 0.000 abstract description 3
- 235000008708 Morus alba Nutrition 0.000 abstract description 3
- 241000722818 Aralia Species 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 29
- 239000006071 cream Substances 0.000 description 10
- 239000006210 lotion Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000002664 inhalation therapy Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 4
- 206010042674 Swelling Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 210000000115 thoracic cavity Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940112822 chewing gum Drugs 0.000 description 3
- 235000015218 chewing gum Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000012676 herbal extract Substances 0.000 description 3
- 229940119170 jojoba wax Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000000323 shoulder joint Anatomy 0.000 description 3
- -1 skin Substances 0.000 description 3
- GRWFGVWFFZKLTI-YGPZHTELSA-N (5r)-4,6,6-trimethylbicyclo[3.1.1]hept-3-ene Chemical compound C1C2CC=C(C)[C@]1([H])C2(C)C GRWFGVWFFZKLTI-YGPZHTELSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000003958 fumigation Methods 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000001256 steam distillation Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- TZNXGARVNMCICB-UHFFFAOYSA-N Camphen Natural products C1CC2C(C)(C)C(=C)C1C2(C)C TZNXGARVNMCICB-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 201000008370 Discitis Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010061172 Gastrointestinal injury Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
- 206010023204 Joint dislocation Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 206010028331 Muscle rupture Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000018286 Shoulder injury Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000020307 Spinal disease Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043248 Tendon rupture Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- FRGAIZLZPOROJH-BKIJVIAGSA-N [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-hydroxy-3-[2-hydroxy-3-(2-hydroxy-3-octadecanoyloxypropoxy)propoxy]propoxy]oxan-2-yl]methyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COCC(O)COCC(O)CO[C@H]1O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@H]1O FRGAIZLZPOROJH-BKIJVIAGSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000002199 base oil Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000012191 relaxation of muscle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/44—Supercritical state
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 천연물 복합오일을 포함하는 통증완화 조성물에 관한 것이다. 더욱 상세하게는 독활, 전나무잎, 상지 및 박하의 천연물 복합오일을 이용하여 항견배통(抗肩背痛)이 있는 피험자의 통증정도 평가(Visual Analog Scale, VAS) 값의 변화량을 제시함으로써 통증을 유의성 있게 감소시킬 수 있는 발명이다.The present invention relates to a pain relief composition comprising a natural product complex oil. More specifically, the use of a natural oil complex oil of fir leaves, fir leaves, upper legs, and peppermint leaves a significant change in the visual analog scale (VAS) value of a subject having anti- In the present invention.
통증 완화는 크게 두 가지 방식에 의해 이루어지는데, 그 중 하나는 통증의 원인은 계속되지만 환자로부터 그 통증을 마스킹(masking)하는 방법이다. 이러한 방식은 많은 진통제(鎭痛劑)의 작용 방식이고, 이러한 진통제는 환자가 진통을 느끼는 것을 방지하기는 하지만, 진통의 근본적인 원인은 차단하지 못하기 때문에, 진통제가 연속적으로 투여되는 것이 요구된다. 보다 효율적인 통증 완화의 다른 방법은 통증을 유발하는 원인을 근본적으로 해결하는 것이다. 즉, 통증의 생리학적 또는 신경전달병을 완화시키면, 통증에 대한 감각이 감소된다.Pain relief is largely accomplished in two ways, one of which is the method of masking the pain from the patient, although the cause of the pain continues. This method is a method of action of many analgesics, and although such analgesics prevent the patient from feeling pain, it is required that the analgesic should be administered consecutively because it can not block the underlying cause of analgesia. Another method of more effective pain relief is to fundamentally address the causes of pain. That is, when the physiological or neurotransmitter of pain is relieved, the sense of pain is reduced.
한편, 진통제와 같은 통증완화제는 구강투여가 일반적이나, 현재 개발된 구강투여용 통증완화제는 다양한 부작용, 예컨대, 간손상, 신장손상, 위장관손상, 중독 및 체중 증가 등의 문제점을 유발하는 경향이 있다. 또한, 구강투여용 통증완화제의 경우에는, 혈류에 진입하기 전에 소화계를 통하여 흡수되어야 하기 때문에, 효능을 발휘하기까지는 다소의 시간을 필요로 한다. 구강투여의 지체(遲滯) 문제를 해결하기 위한 방뻐으로서, 비경구 투여방법, 예컨대, 혈관내 주입 또는 근육내 주입 방식들이 제안되었으나, 이들 방법은 편리하지 않고 비용이 많이 소요되는 문제점이 있고, 병원 외에서는 실시하기가 매우 불편한 문제점이 있다.On the other hand, oral painkillers such as painkillers are generally administered orally, but currently developed oral painkillers have a tendency to cause various side effects such as liver damage, kidney damage, gastrointestinal injury, poisoning and weight gain . In addition, in the case of a pain-relieving agent for oral administration, since it has to be absorbed through the digestive system before entering the bloodstream, it takes some time until the efficacy is demonstrated. Parenteral administration methods such as intravenous infusion or intramuscular injection have been proposed to solve the problem of delay in oral administration, but these methods are not convenient and costly, There is a problem that it is very inconvenient to carry out.
따라서, 국소(局所) 투여방식, 특히 경피(硬皮) 투여 방식으로 통증완화제를 투여하려는 시도들이 꾸준히 이루어지고 있으며, 경피 투여에 적합한 약물 및/또는 약제학적 조성물을 개발하려는 시도들이 이루어지고 있다.Therefore, attempts have been made to administer pain relievers in a local, especially transdermal, mode, and attempts have been made to develop drugs and / or pharmaceutical compositions suitable for transdermal administration.
현재까지는 화학제를 사용한 경피투여용 통증완화제에 관한 개발이 주로 이루어지고 있는데, 이는 단시간에 통증완화의 효과는 얻을 수 있으나, 피부에 자극을 주는 문제점을 갖고 있다. 이에, 최근 피부의 저자극성 경피 투여용 통증완화제를 개발하려는 시도들이 이루어지고 있으나, 한방 천연 재료의 종류 및 이에 따른 효과가 다양하기 때문에, 한방 천연 재료를 혼합하여 사용할 경우 실질적으로 기능성을 인체에 제공할 수 있는지에 대한 연구는 미비한 실정이다.Up to now, the development of a pain relief agent for percutaneous administration using a chemical agent has been mainly performed, which can provide pain relief in a short period of time, but has a problem of irritating the skin. Recently, attempts have been made to develop hypotonic transdermal pain relieving agents for skin. However, since the kinds and effects of the natural herbal ingredients are various, when the natural herbal ingredients are mixed, There is a lack of research on whether it can be done.
한편, 이와 관련한 종래기술로서 하기 비특허문헌 0001은 “독활의 진통 및 항염증 작용기전 연구”이나, 독활은 PGE2 합성과 NO 생성을 통하여 하행성 통증조절 시스템을 활성화시킴으로써 진통과 항염증 작용을 발휘한다는 것이 개시되어 있을 뿐이다. 또한 하기 특허문헌 0001에는 “백복신 등 여러 종류의 한방 추출물을 포함하는 통증 완화용 한방 조성물”이 개시되어 있다. 그러나 이는 통증 완화용 한방 조성물이 근육 또는 관절 부위에 도포됨으로써 기혈 소통, 혈액 순환 개선, 근육·관절 이완 및 통증 완화 등과 같은 효과를 나타낼 뿐이고, 만족할 만한 수준에 이르지 못하고 있다.As a related art related to this, Non-Patent Document 0001 as described below, " Study on analgesic action of anti-inflammatory and anti-inflammatory action ", but the false-positive effect activates analgesic and antiinflammatory action by activating the lowering pain control system through PGE 2 synthesis and NO production It is only disclosed that it exerts. Further, Patent Document 0001 discloses a " herbal composition for pain relief comprising various kinds of herbal extracts such as white bacillus ". However, since the pain relieving herbal composition is applied to muscles or joints, it exhibits effects such as mere blood communication, improvement of blood circulation, relaxation of muscles and joints, and pain relief, and has not reached a satisfactory level.
본 연구자들은 오랜 연구를 통하여 천연물인 독활, 전나무잎, 상지 및 박하의 복합오일을 이용하여 항견배통(抗肩背痛)이 있는 피험자의 통증정도 평가(VAS) 값의 변화량을 제시함으로써 본 발명을 완성하게 되었다.The present inventors have conducted a long study to present a variation of the pain assessment (VAS) value of a subject having anti-vasospasm using a combination oil of natural products, fir leaf, upper and lower meats, It was completed.
본 발명은 천연물인 독활, 전나무잎, 상지 및 박하의 복합오일을 이용하여 항견배통(抗肩背痛)이 있는 피험자의 통증정도 평가(VAS) 값의 변화량을 제시함으로써 통증을 완화시킬 수 있는 천연물 복합오일을 포함하는 조성물을 제공하는 것이다.The present invention relates to a natural product which can alleviate pain by presenting a change amount of pain assessment (VAS) value of a subject having an anti-obsessive-compulsive pain (anti-肩 背痛) using a natural oil, a combination oil of a fir leaf, To provide a composition comprising a complex oil.
본 발명은 독활 오일 25중량%, 전나무잎 오일 30중량%, 박하 오일 25중량%, 상지 오일 20중량%의 천연물 복합오일을 포함하는 것을 특징으로 하는 통증완화 조성물을 제공한다.The present invention provides a pain relief composition comprising a natural product complex oil comprising 25% by weight of a fake oil, 30% by weight of a fir leaf oil, 25% by weight of a peppermint oil, and 20% by weight of a topical oil.
한편, 본 발명에 의한 그 밖의 구체적인 과제의 해결수단은 발명의 상세한 설명에 기재되어 있다. Means for solving the other specific problems according to the present invention are described in the detailed description of the invention.
본 발명에 의한 천연물 복합오일을 포함하는 통증완화 조성물은 천연물인 독활, 전나무잎, 상지 및 박하의 복합오일을 이용하여 항견배통(抗肩背痛)이 있는 피험자의 통증정도 평가(VAS) 값의 변화량을 제시함으로써 통증을 유의성 있게 감소시킬 수 있는 장점이 있다. The pain relieving composition comprising the natural oil complex oil according to the present invention can be used as a pain relieving composition containing a natural oil, a fir leaf, an upper limb and a mint oil mixture, And the amount of pain is significantly reduced by presenting the amount of change.
도 1은 일체의 바디 트리트먼트(Body Treatment)를 할 수 있는 스파 캡슐(Hydro Magic Spa Capsule 1005 제품) 사진이다.Figure 1 is a photograph of a Spa Capsule (Hydro Magic Spa Capsule 1005 product) which can perform an entire body treatment.
이하 본 발명을 실시예 및 적용예에 의해 보다 상세하게 설명한다. Hereinafter, the present invention will be described in more detail with reference to examples and application examples.
본원에서 달리 정의하지 않는 한, 본 발명과 관련하여 사용된 과학 용어 및 기술 용어들은 통상의 기술자에 의해 일반적으로 이해되는 의미를 가질 것이다. 뿐만 아니라, 문맥상 특별히 지정하지 않는 한, 단수 형태의 용어는 그것의 복수 형태도 포함하는 것이며, 복수 형태의 용어는 그것의 단수 형태도 포함할 것이다Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings commonly understood by one of ordinary skill in the art. In addition, unless the context clearly dictates otherwise, the singular form of a term includes plural forms thereof, and plural forms of a term will also include its singular form
본원 발명의 통증완화 조성물은 독활 오일 25중량%, 전나무잎 오일 30중량%, 박하 오일 25중량%, 상지 오일 20중량%의 천연물 복합오일을 포함하는 것을 특징으로 한다.The pain relieving composition of the present invention is characterized by containing a natural product complex oil of 25% by weight of fake oil, 30% by weight of fir leaf oil, 25% by weight of peppermint oil, and 20% by weight of topical oil.
먼저, 본 발명의 상기 천연물 복합오일을 구성하기 위해 사용되는 한방 재료의 특징은 하기와 같다.First, the characteristics of the herbal material used for constituting the natural product complex oil of the present invention are as follows.
독활(獨活)은 땅두릅이라고도 하며, 뿌리줄기 및 뿌리로부터 추출하여 정유(精油, oil)를 얻을 수 있다. 풍한습(風寒濕)으로 인한 근육통, 관절염, 요통, 무릎과 하지 동통에 사용하고 조습작용이 있어 피부가려움증, 외감성 발열, 두통 등에 효과가 있다. 약리작용은 진정, 최면, 진통, 항염증, 혈압강하, 항경련, 항궤양, 햇빛알러지 등에 효과가 보고되었다. It is also called paddy field, and can be extracted from rootstock and root to obtain essential oil. It is used for myalgia, arthritis, low back pain, knee and lower back pain caused by the wind (cold wind), and it has moisturizing effect and it is effective for skin itching, exothermal fever, headache. Pharmacological effects have been reported to be effective in sedation, hypnosis, analgesic, anti-inflammatory, hypotensive, anti-convulsive, anti-ulcer, sunlight allergies.
전나무는 소나무과의 상록교목으로서, 그 잎을 추출하여 얻은 정유에는 α-피넨(Pinen), 캄펜(Camphen), β-피넨(Pinen), 리모넨(Limonen) 등이 함유되어 있으며, 류머티스성 관절염, 요통, 요도염, 폐결핵, 위염, 위궤양 등의 갖가지 염증성 질환 및 가려움, 부스럼, 상처, 종기, 종창 등의 피부에 생기는 피부소양증이 있는 피부에 사용하면 완화되는 효과가 있을 뿐 아니라, 피부건조증, 발진 등의 피부트러블, 건선, 백반증, 피부의 신진대사촉진에 뛰어난 것으로 알려져 있다.The fir is an evergreen tree of the pine tree. The essential oil obtained by extracting the leaf contains Pinen, Camphen, Pinen, Limonen and the like, and rheumatoid arthritis, It is not only effective for alleviating the skin irritation caused by various kinds of inflammatory diseases such as urethritis, pulmonary tuberculosis, gastritis, gastric ulcer, and skin pruritus such as itching, swelling, wounds, swelling and swelling, Skin troubles, psoriasis, vitiligo and skin metabolism.
박하(薄荷)는 인단초(仁丹草)라고도 하며, 잎이나 줄기로부터 추출하여 정유(精油, oil)를 얻을 수 있다. 박하유의 주성분은 멘톨(menthol)이며, 그 밖에 멘톤(menthone) 등을 함유하고 있고, 해열, 소염, 건위, 담즙분비 촉진 및 위장 평활근 억제, 호흡기도의 점액분비 증가, 중추신경 흥분, 자궁수축 등의 효능이 있다.Mint is also called indancho, and it can be extracted from leaves and stems to obtain essential oil. The main ingredient of peppermint is menthol, and it contains menthone, and it promotes the secretion of inflammation, inflammation, dryness, bile secretion, suppression of gastric smooth muscle, increase of mucous secretion of respiratory tract, .
상지(桑枝)는 뽕나무의 주로 봄에 잎이 나기 전에 가는 가지를 잘라 말린 것으로서, 비증(痺症)으로 팔다리의 저림증, 각기 등에 사용하며, 붓는 증상, 고혈압, 팔다리 마비증에도 사용하고, 약리작용으로 지사작용, 항균작용, 장 연동운동 억제작용, 혈압강하작용 등이 보고되어있다. The upper part of the mulberry tree is mainly dried in the spring before the leaf is cut, and it is dried and used for the lower limbs of the limbs due to insomnia. It is also used for the symptoms of swelling, hypertension and limb paralysis. , Antimicrobial action, intestinal peristaltic action, and hypotensive action have been reported.
본 발명에서 독활을 비롯한 천연물 복합오일은 수증기증류법, 냉침법, 유기용제법, 초임계추출법 등의 공지의 다양한 추출법에 의한 추출될 수 있으나, 바람직하게는 초임계추출법을 사용하면 여러 가지 장점이 있다. In the present invention, natural oil complex oil including chewing gum can be extracted by various known extraction methods such as steam distillation method, cold precipitation method, organic solvent method and supercritical extraction method, but preferably using supercritical extraction method has various merits .
초임계추출은 임계점 이상의 유체를 추출체로 사용한 추출법이다. 초임계 유체는 기체와 액체의 중간 정도의 물성을 가지고 있으며, 단순히 온도와 압력의 조절에 의하여 상변화 없이도 물질의 용해성을 변화시켜 많은 물질에 대하여 용해성이 우수한 특성을 가지고 있기 때문에 분리기술의 한 분야로 주목을 받고 있다. 특히, 이산화탄소(CO2)는 임계온도가 31.1℃이고, 임계압력이 73.8bar이므로 낮은 온도에서 추출이 가능하며, 이에 따라 추출된 유효성분의 열에 의한 손상을 막을 수 있으며, 공정 중 에너지 비용도 현저히 줄일 수 있는 등 여러 가지 장점이 있기 때문에 초임계 유체용매로 사용되고 있다.Supercritical extraction is an extraction method using a fluid above a critical point as an extract. Supercritical fluids have medium properties between gas and liquid, and because they have solubility properties for many materials by changing solubility of materials without phase change by simply controlling temperature and pressure, . Particularly, the carbon dioxide (CO 2 ) has a critical temperature of 31.1 ° C. and a critical pressure of 73.8 bar, so that it can be extracted at a low temperature. Thus, it is possible to prevent heat damage to the extracted active ingredient, It can be used as a supercritical fluid solvent.
본 발명에서 천연물 복합오일을 추출하기 위한 건체(乾體) 시료를 수증기증류법으로 추출하면, 각 오일의 회수율은 0.05~2.07%에 불과하다. 그러나 상기 초임계 추출법을 이용하게 되면 오일의 회수율은 기기조건을 적당히 조절하여 50℃ 온도, 150~300bar 압력, 이산화탄소 유량은 30g/min으로 셋팅한 후 90~180분 동안 추출하는 것이 바람직하다. 이어서 얻어진 추출물에 용매로서 70% 주정 또는 케리어 오일에 녹인 다음 10㎛ 필터로 여과한다. 이렇게 하여 얻어진 추출 오일의 수율은 독활 0.31중량%, 전나무 잎 0.24중량%, 상지 3.05중량%, 박하 4.93중량%로 종래의 방법인 수증기증류법으로 추출하는 것보다 현저히 상승될 수 있다.In the present invention, when a dry sample for extracting a natural product complex oil is extracted by a steam distillation method, the recovery rate of each oil is only 0.05 to 2.07%. However, if the supercritical extraction method is used, it is preferable to set the recovery rate of the oil at 50 ° C, 150-300 bar, carbon dioxide flow rate of 30 g / min and 90-180 minutes, respectively. Then, the obtained extract is dissolved in 70% alcohol or a carrier oil as a solvent, and then filtered through a 10 탆 filter. The yield of the extracted oil thus obtained was 0.31% by weight of the extract, 0.24% by weight of the fir leaf, 3.05% by weight of the top, and 4.93% by weight of the peppermint, which can be significantly elevated by the conventional distillation method.
상기에서 얻은 각 오일은 적절한 비율로 혼합되어 천연물 복합오일을 제조할 수 있는데, 그 비율은 독활 오일 25중량%, 전나무잎 오일 30중량%, 박하 오일 25중량%, 상지 오일 20중량%로 혼합하는 것이 바람직하다. Each of the above-obtained oils is mixed in an appropriate ratio to prepare a natural product complex oil. The ratio is 25% by weight of non-fog oil, 30% by weight of fir leaf oil, 25% by weight of peppermint oil and 20% .
한편, 본 발명의 천연물 복합오일을 포함하는 통증완화 조성물에서, 상기 복합오일은 통증완화 조성물에 대해 0.5 내지 3.0중량%의 비율로 포함될 수 있으며, 바람직하게는 1.0 내지 2.0중량%의 비율로 포함되는 것이 바람직하다. 상기 복합오일의 함량이 0.5중량% 미만일 경우에는 통증완화의 뚜렷한 효과를 기대할 수 없고, 3.0중량%를 초과하는 경우에는 함유량 증가에 따른 뚜렷한 효과의 증가가 나타나지 않을 뿐만 아니라 향이 너무 강하고 경제적이지 못하여 사용하기 적합하지 않다.On the other hand, in the pain relief composition containing the natural product complex oil of the present invention, the complex oil may be contained in a proportion of 0.5 to 3.0% by weight, preferably 1.0 to 2.0% by weight, based on the pain relief composition . When the content of the complex oil is less than 0.5% by weight, a significant effect of pain relief can not be expected. When the content of the compound oil is more than 3.0% by weight, the effect is not increased remarkably due to the increase of the content, Not suitable.
본 발명의 바람직한 구현예에서, 천연물 복합오일을 포함하는 통증완화 조성물에 포함되는 성분은 본 발명의 유효성분으로 사용되는 독활, 전나무잎, 박하 및 상지의 복합오일 이외에 생체성분의 활성을 유지시켜주는 다양한 성분들이 포함될 수 있다. In a preferred embodiment of the present invention, the components contained in the pain relieving composition comprising the natural product complex oil are not limited to the complex oil of the chewing gum, fir leaf, peppermint and upper body used as the active ingredient of the present invention, Various components may be included.
또한 본 발명의 천연물 복합오일을 포함하는 통증완화 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 본 발명의 상기 조성물 이외에도 피부과학적으로 허용 가능한 매질 또는 기제를 함유함으로써 피부과학 분야에서 통상적으로 사용되는 국소적용 또는 전신적용할 수 있는 보조제 형태로 제조될 수 있다.In addition, the pain relieving composition comprising the natural oil complex oil of the present invention can be prepared into any formulation conventionally produced in the art. In addition to the composition of the present invention, a skin- Or in the form of adjuvants which can be applied topically or systemically.
상기 천연물 복합오일을 포함하는 통증완화 조성물의 적절한 제형으로는 예를 들면 용액, 겔, 고체 또는 반죽 무수 생성물, 수상에 유상을 분산시켜 얻은 에멀젼, 현탁액, 마이크로에멀젼, 마이크로캡슐, 미세과립구 또는 이온형(리포좀), 비이온형의 소낭 분산제의 형태, 크림, 스킨, 로션, 파우더, 연고, 스프레이 또는 콘실 스틱(conceal stick)의 형태로 제공될 수 있다. 또한, 포말(foam)의 형태 또는 압축된 추진제를 더 함유한 에어로졸 조성물의 형태로도 제조될 수 있다.Suitable formulations of the pain relief composition comprising the natural product complex oil include, for example, solutions, gels, solid or kneaded anhydrous products, emulsions obtained by dispersing oil phase in aqueous phase, suspensions, microemulsions, microcapsules, (Liposome), in the form of a non-ionic follicular dispersion, in the form of a cream, skin, lotion, powder, ointment, spray or conceal stick. It can also be prepared in the form of a foam or an aerosol composition further containing a compressed propellant.
나아가 본 발명의 천연물 복합오일을 포함하는 통증완화 조성물은 독활 등 복합오일에 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온 봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 또는 피부과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 그리고 상기의 성분들은 피부과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다.Further, the pain relieving composition comprising the natural oil complex oil of the present invention may further contain, in addition to the complex oil such as a chewing gum, a fat substance, an organic solvent, a solubilizing agent, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, ), Perfumes, surfactants, water, ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipids Or any other ingredient conventionally used in cosmetics, such as, for example, cosmetics or dermatological sciences. And the above ingredients may be introduced in amounts commonly used in the dermatology field.
본 발명의 천연물 복합오일을 포함하는 통증완화 조성물을 첨가할 수 있는 제품으로는 이에 한정되는 것은 아니지만, 스킨로션, 스킨 소프너, 스킨토너, 수렴화장수, 유연화장수, 영양화장수, 아스트린젠트, 로션, 밀크로션, 모이스처 로션, 영양로션, 바디크림, 마사지크림, 영양크림, 모이스처 크림, 핸드크림, 에센스, 영양에센스, 팩, 비누, 샴푸, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션, 바디클렌저, 트리트먼트, 미용액, 유액, 프레스파우더, 루스파우더, 아이섀도 등의 제형을 포함한다.The product to which the pain relief composition containing the natural product complex oil of the present invention can be added includes, but is not limited to, a skin lotion, a skin softener, a skin toner, a convergent lotion, a softening longevity, a nutritional lotion, an astringent, , Moisture Lotion, Nutrition Lotion, Body Cream, Massage Cream, Nourishing Cream, Moisture Cream, Hand Cream, Essence, Nutrition Essence, Pack, Soap, Shampoo, Cleansing Foam, Cleansing Lotion, Cleansing Cream, Body Lotion, Body Cleanser, Treatment , Serum, milky lotion, press powder, loose powder, eye shadow, and the like.
본 발명의 다른 구현예에 따르면, 본 발명의 천연물 복합오일을 포함하는 조성물은 통증완화 식품 조성물으로 사용될 수 있다. 본 발명의 상기 조성물이 식품 조성물로 제조되는 경우, 유효성분으로서 독활 오일 등 천연물 복합오일 뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제인 타우마틴, 스테비아 추출물(예를 들어, 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다.According to another embodiment of the present invention, the composition comprising the natural product complex oil of the present invention can be used as a pain relief food composition. When the composition of the present invention is prepared as a food composition, it contains not only a natural oil complex oil such as a hardening oil as an active ingredient but also a component which is ordinarily added at the time of manufacturing a food. Examples thereof include protein, carbohydrate, fat, Seasoning and flavoring agents. Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors such as tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharine, aspartame, etc.) can be used.
또한 본 발명의 식품 조성물이 드링크제로 제조되는 경우에는 본 발명의 복합오일 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 두충 추출액, 대추 추출액, 감초 추출액 등을 추가로 포함시킬 수 있다.When the food composition of the present invention is prepared as a drink, it may further contain citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract, licorice extract etc. in addition to the complex oil of the present invention .
이하, 실시예 및 실험예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다. Hereinafter, the present invention will be described in more detail with reference to Examples and Experimental Examples. It is to be understood by those skilled in the art that these embodiments are only for illustrating the present invention and that the scope of the present invention is not construed as being limited by these embodiments.
<실시예> 천연물 복합오일의 제조<Examples> Production of natural oil complex oil
깨끗하게 세척 및 건조된 독활, 전나무잎, 상지 및 박하를 각각 2㎏씩 준비하여 초임계추출기(일신오토클레이브 제품)에 투입한 후 400bar, 60℃에서 2시간 동안 초임계 유체인 이산화탄소(CO2)를 흘려주면서 초임계 상태에서 추출함으로써 독활 오일 등 천연물 오일을 각각 제조하였다. 각 오일의 수율은 독활 0.31%, 전나무 잎 0.24%, 상지 3.05%, 박하 4.93%이었다.(2) Each of the cleaned and dried fecal leaves, fir leaves, upper limbs and peppermint leaves were put into a supercritical extractor (ILSIN AUTOCLEVED product), and then carbon dioxide (CO 2 ), supercritical fluid, And extracted from the supercritical state to produce a natural oil such as a fake oil. The yields of each oil were 0.31%, 0.24%, 3.05%, and 4.93%, respectively.
상기에서 얻은 각 천연물 오일은 적절한 비율로 혼합되어 천연물 복합오일을 제조할 수 있는데, 그 비율은 독활 오일 25중량%, 전나무잎 오일 30중량%, 박하 오일 25중량%, 상지 오일 20중량%로 혼합하는 것이 바람직하였다. Each of the natural oils obtained above is mixed in an appropriate ratio to prepare a natural product complex oil. The ratio is 25% by weight of essential oil, 30% by weight of fir leaf oil, 25% by weight of peppermint oil and 20% .
<비교예 1>≪ Comparative Example 1 &
투명한 액체상태인 호호바(Jojoba) 오일(순도 100%)을 (주)힐링네이쳐로부터 구입하여 사용하였다.Jojoba oil (100% purity) in a transparent liquid state was purchased from Healing Nature Co., Ltd. and used.
<비교예 2> ≪ Comparative Example 2 &
백복신, 죽여, 향부자, 감국, 석창포, 원지, 산조인, 황련, 박하 및 연자육을 1:1:1:1:1:1:1:1:1:1.6의 중량비로 혼합하여 만든 혼합물을 2기압, 150℃에서 2시간 동안 증자한 후, 건조하고 나서 열수추출하여 얻은 한방 추출물을 사용하였다.1: 1: 1: 1: 1: 1.6 in a weight ratio of 1: 1: 1: 1: 1: The extracts were heated at 150 ℃ for 2 hours, dried and then extracted with hot water.
<제조예> 바디 크림의 제조≪ Preparation Example > Preparation of body cream
바디크림은 하기 [표 1] 성분표의 구성에 따라 제조하였다. 먼저, 수상과 유상을 계량하여 각각을 70~75℃까지 가열하고, 수상을 유화기를 이용하여 고르게 혼합한 후 유상을 가하여 유화를 시켰다. 유화시킨 후에 안정제를 계량하여 투여하고, 유화기로 고르게 교반하면서 유화기의 속도를 감속하며 35~40℃까지 냉각하였다. 첨가제를 계량하여 4번에 투여한 후에 서서히 교반하여 첨가제가 고르게 분포하도록 한 다음, 감압조건에서 탈포시키고 약 3일간 실온에서 숙성시켜 바디크림을 제조하였다. Body creams were prepared according to the composition of the following table in Table 1. First, the water phase and the oil phase were weighed and heated to 70 to 75 DEG C, respectively. The water phase was uniformly mixed using an emulsifier, and the oil phase was added to the oil phase. After the emulsification, the stabilizer was metered and administered. The speed of the emulsifier was reduced while stirring with an emulsifier, and the emulsion was cooled to 35 to 40 ° C. After the additives were weighed and dosed 4 times, the mixture was gradually stirred to distribute the additives evenly. The mixture was degassed under reduced pressure and aged at room temperature for about 3 days to prepare a body cream.
<실험예> 천연물 복합오일의 효능 시험<Experimental Example> Effectiveness test of natural oil complex oil
본 발명의 실시예 및 비교예 1, 2에 따른 복합오일의 효능을 VAS 측정을 통해 시험하였다. VAS(Visual analog scale)는 환자의 통증 정도를 파악하는 테스트 방법으로서, 10cm 길이의 선으로 한쪽 끝에는 통증이 없음을 기록(0점)하고, 다른 편의 끝에는 상상 가능한 가장 심한 고통을 기록(10점)하도록 되어 있는 것이다. 환자는 측정 당시에 느끼는 통증을 이 선위에 적절한 점수를 기입한다. 이 방법은 한 사람의 환자를 다른 환자와 비교할 수는 없지만, 동일 환자에 대해서는 통증이 어떻게 변동하고 있는지를 상당히 정확히 파악할 수 있는 장점이 있는 측정 방법이다. 기타 효능의 시험을 위한 세부 조건은 다음과 같다.The efficacy of the compounded oils according to Examples of the present invention and Comparative Examples 1 and 2 was tested by VAS measurement. The visual analog scale (VAS) is a test method to determine the degree of pain in a patient. It records 10 points of no pain at one end with a line of 10cm length, records the most imaginable pain at the end of the other piece (10 points) . Patients should fill in the appropriate score for the pain they feel at the time of the measurement. Although this method can not compare one patient to another, it is a measurement that has the advantage of being able to pinpoint how the pain is changing for the same patient. The detailed conditions for testing other efficacy are as follows.
1. 피험자의 선정/제외기준1. Selection criteria for subjects
1) 대상 질환 및 적응증 : 항견배통(경항부, 견부에서 상배부로 이어지는 통증, 경항하부의 좌우양측, 상지와 구간이 접합하는 부위의 통증) 1) Target disease and indications: Attachment pain (Pain at the junction between the upper and lower limbs, upper and lower limbs,
2) 피험자의 선정기준 2) Selection criteria of subjects
① 만 19~65세의 남녀① Men and women aged between 19 and 65
② 경항부, 견부에서 상배부로 이어지는 통증[경항통, 견통, 견배통]이 있는 자로서, 아래와 같은 상병명에 해당하는 자 ② Those who have the pain from the shoulder part, the shoulder part to the upper part,
- 경추/흉추/어깨관절의 염좌 및 긴장[S134/S233/S434] - sprain and torsion of the cervical vertebra / thoracic / shoulder joints [S134 / S233 / S434]
- 근근막통증후군, 목/어깨부분/어깨관절[M79180C/M79110/M7911E] - myofascial syndrome, neck / shoulder part / shoulder joint [M79180C / M79110 / M7911E]
- 기타 근통, 목/어깨부분/어깨관절/견갑골[M79188C/M79118/M79118E/M79118C] - Miscellaneous pains, neck / shoulder parts / shoulder joints / scapula [M79188C / M79118 / M79118E / M79118C]
- 기타 등통증, 경부/경흉추부[M5482/M5483] - Other pain, neck / neck thoracic spine [M5482 / M5483]
- 흉추통증, 경흉추부/흉추부[M5463/M5464] - Thoracic pain, light thoracic / thoracic [M5463 / M5464]
③ visual analog scale 상 3점 이상인 자③ A person with three or more points on visual analog scale
④ 연구자와 원활한 의사소통이 가능하며, 시험 준수사항을 잘 따를 수 있는 자 ④ Those who are able to communicate with the researcher and follow the test compliance
⑤ 시험참여에 앞서 시험의 목적, 내용, 시험제품의 특성 등에 대하여 충분히 설명을 듣고 자발적으로 인체시험에 참여를 결정하고 서면으로 동의한 자 ⑤ Prior to participating in the test, he / she should be fully informed about the purpose of the examination, the contents of the test, the characteristics of the test product, etc. and voluntarily decided to participate in the human test and agreed in writing
3) 피험자의 제외기준 3) Exclusion criteria for subjects
① 주된 어깨 손상 및 수술 과거력이 있는 자① Those with major shoulder injury and history of surgery
② 외상성 질환(골절, 건파열, 근육파열, 탈구, 아탈구)을 가진 자② Those who have traumatic diseases (fracture, tendon rupture, muscle rupture, dislocation, subluxation)
③ 골질환(골수염, 골종양, 골육종, 골암), 척추 및 척수질환(경추추간판탈출,경추추간판염, 경추추간공 협착성 신경근증) 혹은 심각한 신경학적 증상을 동 반한 자③ patients with severe neurological symptoms, such as bone diseases (osteomyelitis, bone tumors, osteosarcoma, bone cancer), spinal and spinal diseases (cervical disc herniation, cervical discitis, cervical intervertebral stenosis neuromuscular)
④ 내과계 질환(내장성 관련통, 류마토이드양 관절염, 판코스트 증후군), 신장 및 간장 질환, 조혈성 질환을 가진 자④ Those who have internal medicine diseases (visceral pain, rheumatoid arthritis, panchost syndrome), kidney and liver diseases, hematopoietic diseases
⑤ 협심증, 심근경색, 급성전염병에 대해 3개월 이내에 증상이 있었던 기왕력을 갖는 자⑤ Persons with previous history of symptoms of angina, myocardial infarction, acute infectious disease within 3 months
⑥ 온천의 일반 금기에 해당하는 다음 상황에 놓인 자 : 38℃ 이상의 발열자, 상기도 감염 증상을 호소하는 자, 인후염, 피부 화농, 음주 상태, 임신 초기와 말기, 활동성 결핵, 악성 종양, 백혈병, 호흡부전,급성기 뇌졸중, 출혈성 질환⑥ People who are exposed to the general taboo of hot springs in the following situations: those who have a temperature above 38 ℃, who complain of upper respiratory infection, sore throat, skin rash, drinking status, early and late pregnancy, active tuberculosis, Respiratory failure, acute stroke, hemorrhagic disease
⑦ 부신피질 호르몬, 항경련제 등 임상시험에 영향을 줄 수 있는 약물을 최근 1 주일 이내에 복용중인 자⑦ Those who are taking medications that may affect clinical trials such as corticosteroids and anticonvulsants within the last week
⑧ 임신 또는 수유중인 여성과 임신 가능성이 있는 여성⑧ Women who are pregnant or lactating and women who are pregnant
⑨ 임상시험 시작 전 3개월 내에 중재 및 시술의 임상시험에 참여한 자⑨ Those who participated in clinical trials of intervention and treatment within 3 months prior to commencement of clinical trial
⑩ 위의 사항들 외에 시험자의 판단으로 시험의 수행이 곤란하다고 판단되는 자 ⑩ Any person other than the above who is deemed difficult to perform the test at the discretion of the tester
4) 목표피험자 수 : 실험군 15명, 대조군(Placebo) 15명, 총 30명의 피험자를 대상으로 임상연구 수행 4) Number of target subjects: 15 subjects in the experimental group and 15 subjects in the control group (Placebo)
2. 임상시험방법 2. Clinical Test Methods
1) 임상시험의 개요 1) Outline of clinical trial
① 전향적(Prospective), 이중맹검(double blind), 무작위 배정(randomization), 단일기관(single center) 임상시험Prospective, double blind, randomization, single center clinical trials
② 등록된 대상자들은 1주 동안 2~4일 간격으로 총 2회 향기건식 흡입요법과 스파 프로그램을 기관에서 시행하게 된다.② Registered subjects will have a total of 2 fragrance dry inhalation therapy and spa program at the institution every 2 ~ 4 days for 1 week.
2) 임상시험용 제품 사용방법 2) How to use products for clinical tests
본 시험의 대상자당 시험기간은 총 1~3주로 진행한다. 대상자는 본 임상시험 기간 중 총 3~4회 방문한다. 시험제품은 향기건식 흡입요법, 비쉬 스파 프로그램 수치료 순으로 치료를 시행하게 된다.The duration of the test per subject is 1 to 3 weeks in total. The subjects will be visited three to four times during the period of the trial. The test product will be administered in the order of aroma dry inhalation therapy and Vishwa Spa program water treatment.
① 향기건식 흡입요법 ① fragrance dry inhalation therapy
실시예 및 비교예에 의한 오일 2방울을 거즈에 떨어뜨려 대상자의 코 5cm 앞에 대고 5회의 심호흡을 먼저 시행하고, 이후 5분간 일반적인 흡입을 통해 흡입하도록 한다. Two drops of oil according to the examples and the comparative example are dropped on the gauze, and 5 breaths are performed in front of the subject's nose 5 cm. Then, the breath is first sucked through general suction for 5 minutes.
② 비쉬 스파 프로그램② Vishwa Spa Program
개인의 신체의 특성에 따른 트리트먼트 실현이 가능하고, 설정 온도가 되면 자동으로 훈증 시스템이 멈추고, 다시 온도가 다운되면 자동으로 훈증이 켜져 중증 환자를 위한 장시간 케어 가능, 케어 및 치료 시간설정이 20분에서 30분 설정이 가능하다(대만 제품명 : Hydro Magic Spa Capsule 1005, 도면 1 참조). It is possible to realize the treatment according to the characteristics of the person's body. When the set temperature is reached, the fumigation system automatically stops. When the temperature goes down again, the fumigation is automatically turned on. (Taiwan product name: Hydro Magic Spa Capsule 1005, see drawing 1).
3. 임상검상 항목 및 관찰 검사방법 3. Clinical examination item and observation method
1) 검사항목 1) Inspection items
① 대상자 기초정보① Subject Basic Information
방문 1에서 대상자의 성별, 생년월일을 기록하고 과거 병력과 약물투여력 등의 대상자 기초정보를 기록한다. 방문 2, 3, 4에서는 지난 방문 이후에 발생한 질병/질환 및 약물 사용 여부에 대하여 조사한다. Record the gender and date of birth of the subject in Visit 1 and record basic information about the subject such as past history and drug dosage. At visits 2, 3 and 4, investigate the disease / illness and drug use after the last visit.
② 활력징후 : 5분 안정을 취한 후에 혈압, 맥박을 매 방문 시마다 측정한 다음 기록한다. (방문 1, 2를 동일한 날 시행한 경우는 방문 1의 검사치를 동일하게 사용한다.)② Signs of vitality: After taking 5 minutes of stabilization, measure blood pressure and pulse every visit, then record. (If visits 1 and 2 are carried out on the same day, the same test value is used for visit 1.)
③ 선정제외기준 확인 : 방문 1에 실시하고 무작위 배정 전에 확인한다.③ Confirmation of selection exclusion criteria: Visit 1 and confirm before random assignment.
④ 임신반응 검사(가임기 여성만 해당) : 방문 1에서 시행한다.④ Pregnancy test (only for pregnant women): It is performed at visit 1.
⑤ 향기건식 흡입요법 : 방문 2, 3에 실시한다. ⑤ Scent dry inhalation therapy: It is carried out at visit 2, 3.
⑥ 스파프로그램 시행 : 방문 2, 3에 실시한다. ⑥ Implementation of Spa Program: Visit 2 or 3.
⑦ 통증 정도(VAS) 평가 : 방문 1, 2, 4에서 실시한다.⑦ Assessment of Pain Level (VAS): Visits 1, 2 and 4.
2) 검사방법 2) Inspection method
① 통증 정도(VAS) 평가① Evaluation of pain (VAS)
방문1, 2, 4에서 대상자가 느끼는 통증의 정도를 아래와 같은 10cm 선분 위에 대상자가 직접 표시하도록 하고, 그 길이를 측정한다. 임상시험제품 사용 전후의 통증 정도를 비교하여 통증 개선도를 평가한다. The subjects were asked to indicate the degree of pain felt by the subjects at visit 1, 2, and 4 directly on the 10 cm segment below, and measure their length. Clinical test The degree of pain improvement is evaluated by comparing the degree of pain before and after use of the product.
3) 임상시험 절차 3) Clinical Trial Procedures
① 1차 수행(방문 1)① Primary performance (visit 1)
- 서면 동의서 취득 및 스크리닝 검사 수행 - Acquisition of written consent and screening test
- 인구학적 조사, 활력징후, 병력 및 이전 약물 투여력 확인, 임신반응 검사 - demographic surveys, signs of vitality, history and previous drug dosing, pregnancy test
- 통증 정도(VAS) 평가 - Evaluation of Pain (VAS)
② 2차 수행(방문 2, Baseline, 1차 수행과 동시 진행 가능)② Secondary performance (visit 2, Baseline, simultaneous with 1st performance)
- 무작위 배정 및 등록번호 부여 - Assign random number and registration number
- 활력징후 측정 - Measurement of signs of vitality
- 통증 정도(VAS) 평가 - Evaluation of Pain (VAS)
- 향기건식 흡입요법 시행 - Fragrance dry inhalation therapy enforcement
- 스파 프로그램 시행 - Spa program enforcement
③ 3차 수행(방문 3, 4일±2)③ Third performance (visit 3 or 4 days ± 2)
- 활력징후 측정 - Measurement of signs of vitality
- 향기건식 흡입요법 시행 - Fragrance dry inhalation therapy enforcement
- 스파 프로그램 시행 - Spa program enforcement
④ 4차 수행(방문 4, 6일±3)④ Fourth performance (visit 4, 6 days ± 3)
- 활력징후 측정 - Measurement of signs of vitality
- 통증 정도(VAS) 평가 - Evaluation of Pain (VAS)
4. 평가 및 해석 4. Evaluation and Interpretation
항견배통 환자를 대상으로 방문 2(baseline)에 측정한 VAS 값과 시험제품인 실시예의 독활 복합오일과 대조제품인 비교예 1의 호호바오일, 비교예 2의 한방 추출물을 적용한 후 시험군과 대조군에 대해 방문 4에 측정한 VAS 값의 변화량에 대한 기술통계량(평균, 표준편차, 중앙값, 최소값, 최대값)을 제시한다.The VAS values measured at the baseline of visit 2 and the mixed crude oil of the test product example and the comparative example 1 jojoba oil and the herbal extract of the comparative example 2 were applied to the test subjects and the control group (Mean, standard deviation, median, minimum, and maximum values) for the variation of the VAS value measured in step 4.
유효성 평가변수는 방문 2(Baseline) 대비 방문 4(6일±3)의 VAS 변화량이다. 따라서 해당 변수 값의 분포가 정규성 가정을 크게 벗어나지 않는 한 Student’t-test를 사용해 비교한다. 만약 정규성 가정을 만족하지 않으면 Wilcoxon rank sum test를 활용한다.The efficacy variable is the change in VAS for Visit 4 (6 days ± 3) versus Visit 2 (Baseline). Therefore, we use the Student't-test to compare the distribution of the variable values unless they deviate significantly from the normality assumption. If the normality assumption is not satisfied, use the Wilcoxon rank sum test.
첫 번째 단계에는 시험군(독활오일)과 대조군(호호바오일, 한방 추출물) 각각에 대해 방문 2 대비 방문 4의 VAS 점수의 변화의 유의성 검정을 위해 대응표본 t-test를 실시한다. 이때 시험군 및 대조군 각 군에서 통계적으로 유의하게 통증 감소 효과를 보인다면 두 번째 단계를 진행한다. In the first step, a corresponding sample t-test is conducted to test the significance of the changes in the VAS scores of visit 4 versus visit 2 for the test group (simple oil) and the control group (jojoba oil, herbal extract). At this time, if the test group and the control group show statistically significant pain reduction effect, the second step is carried out.
두 번째 단계는 시험군과 대조군 사이에 일차 유효성 평가 변수인 방문 2 대비 방문 4의 VAS 점수의 변화를 Student’t-test 또는 Wilcoxon rank sum test를 사용하여 비교한다.The second step is to compare the changes in the VAS scores of visit 4 versus visit 2, the primary efficacy variable between the test and control groups, using the Student't-test or the Wilcoxon rank sum test.
5. 유효성 결과5. Validity Results
1) 방문 2(Baseline) 대비 방문 4의 VAS 변화량 1) VAS variation of visit 4 versus baseline 2
본 시험의 유효성 평가변수는 Baseline(방문 2) 대비 최종 평가시점(방문 4)의 VAS 변화량으로, 이에 관한 평균과 표준편차, 최소값 및 최대값 등을 제시하였다. 유효성 평가는 시험군 및 대조군 각각을 대상으로 분석하여 시행하였고, 그 결과는 [표 3]과 같다.The validity test variable of this study is VAS variation of baseline (visit 2) and final evaluation time (visit 4), and the mean, standard deviation, minimum value, and maximum value of the VAS variation are presented. The validity was evaluated by analyzing the test group and the control group, and the results are shown in [Table 3].
우선 방문 2(Baseline)에서의 시험군과 대조군 간의 비교에서 P1=0.490, P2=0.298 로 VAS 데이터 값에 대한 이들 군간의 차이는 보이지 않았다. 각 군내에서 시험 전후 변화를 살펴보면 실험군은 평균 6.22에서 4.11로 가장 유의하게 감소하였으며, 대조군 1이 4.23에서 3.35, 대조군 2는 5.01에서 3.89로 시험 후 각각 유의하게 통증이 감소하였다.In the comparison between the test group and the control group in the first visit 2 (baseline), there was no difference in the VAS data between these groups with P1 = 0.490 and P2 = 0.298. In each group, the changes in the test group showed the most significant decrease from 6.22 to 4.11 in the experimental group. In the control group 1, 4.23 to 3.35 and in the control group 2, the pain decreased significantly from 5.01 to 3.89.
시험군의 시험전후 VAS 변화량의 평균값을 대조군과 비교해보면, 시험군은 -2.11±0.19, 대조군 1은 -0.88±0.43, 대조군 2는 -1.12±0.32로 나타나 대조군에 비해 유의성 있는 차이를 나타내었다. Compared with the control group, the mean value of the VAS change before and after the test was -2.11 ± 0.19 in the test group, -0.88 ± 0.43 in the control group 1, and -1.12 ± 0.32 in the control group.
* P1, P2 : Students' t-test* P1, P2: Students' t-test
2) 결론 2) Conclusion
VAS의 경우 피험자의 주관적인 통증을 수치화 한 것으로, 임상시험 전에 비해 임상시험 후에 통증이 유의하게 감소하였다. VAS 군간의 비교에서는 시험군인 실시예의 복합오일은 -2.11±0.19, 대조군 1은 -0.88±0.43, 대조군 2는 -1.12±0.32로 의미는 차이가 있는 것으로 나타났다.In the case of VAS, the subject's subjective pain was quantified and the pain was significantly reduced after the clinical trial compared to before the clinical trial. In the comparison between the VAS groups, the mean values of the mixed oils in the test group were -2.11 ± 0.19, -0.88 ± 0.43 in the control group 1, and -1.12 ± 0.32 in the control group.
상기 유효성 평가를 바탕으로 시험군의 경우 대조군 1, 2에 비해 가장 유의한 효과가 있는 것으로 나타났고, 통계적으로 유의한 변화가 있음을 확인하였는바, 결과적으로 VAS인 유효성 평가 변수의 유효성 확인 및 안정성 확인이 가능했다. Based on the validity evaluation, the test group showed the most significant effect as compared with the control group 1 and 2, and it was confirmed that there was a statistically significant change. As a result, the validity and stability It was possible to confirm.
상기에서는 본 발명의 실시예를 참조하여 설명하였지만, 해당 기술 분야에서 통상의 지식을 가진 자라면 하기의 특허청구의 범위에 기재된 본 발명의 사상 및 영역으로부터 벗어나지 않는 범위 내에서 본 발명을 다양하게 수정 및 변경시킬 수 있음을 이해할 수 있을 것이다. 전술한 실시예 외의 많은 실시예들이 본 발명의 특허청구범위 내에 존재한다.It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the invention as defined in the following claims And changes may be made without departing from the spirit and scope of the invention. Many embodiments other than the above-described embodiments are within the scope of the claims of the present invention.
Claims (6)
25% by weight of essential oil, 30% by weight of fir leaf oil, 25% by weight of peppermint oil, and 20% by weight of topical oil as an effective ingredient.
상기 천연물 복합오일은 독활, 전나무 잎, 박하, 상지로부터 초임계 유체로서, 이산화탄소(CO2)를 사용하는 초임계 추출법에 의하여 각각 추출된 후에 혼합되는 것을 특징으로 하는 천연물 복합오일을 포함하는 것을 특징으로 하는 통증완화 조성물.
The method according to claim 1,
The natural products combined oil is characterized by including a natural composite oil characterized in that the mixture after the Aralia cordata, fir needle, peppermint, each extracted as the supercritical fluid from the upper limb, by the supercritical extraction method using carbon dioxide (CO 2) ≪ / RTI >
상기 추출은 50℃, 150~300bar에서 90~180분 동안 이루어지는 것을 특징으로 하는 천연물 복합오일을 포함하는 것을 특징으로 하는 통증완화 조성물.
3. The method of claim 2,
Wherein the extraction is performed at 50 DEG C and 150 to 300 bar for 90 to 180 minutes.
상기 천연물 복합오일은 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제, 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온 봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭으로부터 선택되는 적어도 하나를 더 포함하는 것을 특징으로 하는 통증완화 조성물.
4. The method according to any one of claims 1 to 3,
The natural product complex oil may be at least one selected from the group consisting of fatty substances, organic solvents, solubilizers, thickening and gelling agents, softening agents, antioxidants, suspending agents, stabilizers, foaming agents, perfumes, surfactants, water, ionic or nonionic emulsifiers, Wherein the composition further comprises at least one selected from an ionic blocking agent and a chelating agent, a preservative, a vitamin, a blocking agent, a wetting agent, an essential oil, a dye, a pigment, a hydrophilic or lipophilic active agent and a lipid vesicle.
상기 천연물 복합오일은 천연물 조성물 총량에 대하여 0.5~3.0중량%로 함유하는 것을 특징으로 하는 통증완화 조성물.
5. The method of claim 4,
Wherein the natural oil complex oil comprises 0.5 to 3.0% by weight based on the total weight of the natural composition.
상기 천연물 복합오일을 유효성분으로 포함하는 것을 특징으로 하는 통증완화 식품 조성물.
4. The method according to any one of claims 1 to 3,
A pain relief food composition comprising the natural product complex oil as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170113032A KR101962894B1 (en) | 2017-09-05 | 2017-09-05 | Composition for Pain Relief Comprising Natural Combined Oil |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170113032A KR101962894B1 (en) | 2017-09-05 | 2017-09-05 | Composition for Pain Relief Comprising Natural Combined Oil |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20190026317A true KR20190026317A (en) | 2019-03-13 |
KR101962894B1 KR101962894B1 (en) | 2019-07-31 |
Family
ID=65762032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170113032A KR101962894B1 (en) | 2017-09-05 | 2017-09-05 | Composition for Pain Relief Comprising Natural Combined Oil |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101962894B1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040041865A (en) * | 2002-11-12 | 2004-05-20 | 김경화 | herb medicine for remedying cold |
KR20120021409A (en) * | 2010-07-30 | 2012-03-09 | 윤여훈 | The manufacturing method of firs's leaf oil refning which relaxes the skin pruritis |
KR101551375B1 (en) | 2013-11-26 | 2015-09-08 | 장진택 | Oriental plant extracts for attenuating pain |
KR101578068B1 (en) * | 2015-04-08 | 2015-12-16 | 김경일 | Health supplementing food for alleviating symptoms of joint pathologies and a preparation method thereof |
KR101714543B1 (en) * | 2016-09-02 | 2017-03-13 | 강원대학교산학협력단 | Aroma composition for psycholigical stability and reducing stress comprising Schisandra chinensis essential oil and Angelica gigas essential oil as effective component |
-
2017
- 2017-09-05 KR KR1020170113032A patent/KR101962894B1/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040041865A (en) * | 2002-11-12 | 2004-05-20 | 김경화 | herb medicine for remedying cold |
KR20120021409A (en) * | 2010-07-30 | 2012-03-09 | 윤여훈 | The manufacturing method of firs's leaf oil refning which relaxes the skin pruritis |
KR101551375B1 (en) | 2013-11-26 | 2015-09-08 | 장진택 | Oriental plant extracts for attenuating pain |
KR101578068B1 (en) * | 2015-04-08 | 2015-12-16 | 김경일 | Health supplementing food for alleviating symptoms of joint pathologies and a preparation method thereof |
KR101714543B1 (en) * | 2016-09-02 | 2017-03-13 | 강원대학교산학협력단 | Aroma composition for psycholigical stability and reducing stress comprising Schisandra chinensis essential oil and Angelica gigas essential oil as effective component |
Non-Patent Citations (1)
Title |
---|
독활의 진통 및 항염증 작용기전 연구(2005. 12. 경원대학교 박사학위 논문) |
Also Published As
Publication number | Publication date |
---|---|
KR101962894B1 (en) | 2019-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5191988B2 (en) | Nanoliposomes using esterified lecithin, method for producing the same, and composition for preventing or treating skin diseases comprising the same | |
KR101006693B1 (en) | Cosmetic compositions improving atopic dermatitis by complex function of damaged skin barrier repairing by lipid exchange and desensitizing, anti-inflammation and its manufacturing method thereof | |
TW457094B (en) | Topical composition for enhancing lipid barrier synthesis | |
JPH02117619A (en) | Cosmetic composition and paramedical composition | |
JP2010059161A (en) | Composition for makeup or skin disease containing mixture of essential oil and its use especially for care for sensitive skin or sensitized skin | |
JP2001039848A (en) | Skin lotion | |
US5571794A (en) | Non-invasive novel method fo cosmetic lip augmentation | |
KR101715294B1 (en) | Composition having effects of skin moisturizing, exfoliating, improving skin elasticity, inhibiting erythema, anti-wrinkle or improving skin photoaging comprising diosmin or salt thereof | |
KR101257435B1 (en) | The cosmetic composition for alleviating atopy and contact dermatitis containing sage, Melissa officinalis, Gelidium amansii and Allium cepa | |
CN105770237A (en) | Foaming agent with itching-relieving and inflammation-diminishing effects and preparation method of foaming agent | |
JP6059510B2 (en) | Ceramide production promoter | |
KR101962894B1 (en) | Composition for Pain Relief Comprising Natural Combined Oil | |
KR101477073B1 (en) | Cosmetic composition for skin whitening comprising Ginseng seeds extract | |
CN114948769A (en) | Emulsified smearing mask with relieving and repairing effects | |
KR20190070081A (en) | Cosmetic Composition Comprising Mixing Extract of Plant Belonging to the Curcuma Longa and Zingiber Officinale for Improving Skin | |
WO2021048961A1 (en) | Agent for suppressing/improving bad skin caused by fatigue and/or stress and screening method for agents for suppressing/improving bad skin caused by fatigue and/or stress | |
KR101962892B1 (en) | Natural Compositions Having Mind and Body Stability | |
JP3183741B2 (en) | Complexion improver | |
KR101322850B1 (en) | The cosmetic composition for pore-minimizing and inhibition of Sebum Secretion containing the extract of leaves of Mentha arvensis var. piperascens, wheat bud, and Platycodon grandiflorum | |
JP2011037721A (en) | Skin care preparation for external use exhibiting sleep-improving action | |
KR101566694B1 (en) | Method For Increasing Yield Of Ginseng Seed Extract | |
CN110269926A (en) | Middle benefit gas, which is relaxed, warms up composition and its preparation method and application | |
JPH11343497A (en) | Cosmetic | |
EA039464B1 (en) | Topical skin care compositions | |
JP6151027B2 (en) | Ceramide production promoter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |